Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccines
AlphaVax Announces Full Enrollment in Phase I/II Study of Active Immunotherapy in Patients with Advanced or Metastatic Cancer
May 27th, 2009
AlphaVax announced the completion of enrollment in a Phase I/II CEA cancer immunotherapy study being conducted by the Duke University Comprehensive Cancer Center, Durham, NC. This Phase I/II study is an open-label, dose-escalation study to evaluate the safety and immunogenicity of carcinoembryonic antigen (CEA(6D))-expressing virus-like replicon particle (VRP) immunotherapy in patients with advanced or metastatic CEA-expressing malignancies. CEA is tumor protein found on many types of cancer including colorectal, pancreatic, gastric, breast, ovarian, and lung. The Phase I study consists of a dose escalation at 3 dosage levels of CEA-expressing VRP and the Phase II...
Source: Vaccine Weekly (2009-05-27)
|
